Company intelligence / Profile preview

Solartint

Ownership: Private
Development stage: Other

Overview

Solar Biotech has developed proprietary microbial strains and advanced bioprocessing technologies enabling sustainable production of diverse bio-based products. The company became profitable early but filed for Chapter 11 due to overexpansion. It was acquired in late 2024 by Pictor Biotech. Now part of a unified group with GPC Bio (France) and Eleszto Genetika (Hungary), it offers vertically integrated synthetic biology solutions from R&D through commercial manufacturing. No clinical results are reported since it does not develop drugs.

Modalities: Precision fermentationMicrobial fermentation
Industry: Non-Drug Biotech

Partnerships

Ingredion (invested prior to acquisition)partnerships with major industrial biotech/food companies via GPC Bio

Beyond the preview

Go deeper on Solartint.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solartint.

Explore the full profile